Company intelligence / Profile preview

Estrella Immunopharma, Inc.

Emeryville, California, United Statesestrellabio.com ↗

Ownership: Public · ESLA
Development stage: Phase 1

Overview

The company’s lead candidate EB103 has shown a complete response in the first patient treated in its STARLIGHT‑1 Phase I/II trial for B‑cell malignancies. Early safety and efficacy results are promising; additional programs are in preclinical development targeting both cancer and autoimmune disease.[8]

Therapeutic areas: HematologyImmunologyOncology
Modalities: T-cell therapies (ARTEMIS® T-cell platform)Cell therapy[1][3][6]
Industry: Biotech

Drug pipeline

3 assets

EB103

2 more assets in the full pipeline.

Request access →

Partnerships

Imugene LimitedEureka Therapeutics

Financials

Market cap: $27.2M
Total revenue: $0
Enterprise value: $27.1M

Beyond the preview

Go deeper on Estrella Immunopharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Estrella Immunopharma, Inc..

Explore the full profile